Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
100 Leser
Artikel bewerten:
(0)

Pro-Trader Daily: Earnings Review and Free Research Report: Thermo Fisher's Revenue Surged 14.03%; EPS Jumped 12.5%

Research Desk Line-up: PerkinElmer Post Earnings Coverage

LONDON, UK / ACCESSWIRE / November 10, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher"), which can be viewed by registering at http://protraderdaily.com/optin/'symbol=TMO, following the Company's disclosure of its financial results on October 25, 2017, for the third quarter of the fiscal year 2017. The leading manufacturer of analytical instruments and services exceeded revenue and earnings per share (EPS) estimates. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Medical Laboratories & Research industry. Pro-TD has currently selected PerkinElmer, Inc. (NYSE: PKI) for due-diligence and potential coverage as the Company reported on November 02, 2017, its financial results for Q3 2017 which ended on October 01, 2017. Register for a free membership today, and be among the early birds that get access to our report on PerkinElmer when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on TMO; also brushing on PKI. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/'symbol=TMO

http://protraderdaily.com/optin/'symbol=PKI

Earnings Reviewed

Thermo Fisher's total revenues were $5.12 billion for Q3 FY17 compared to $4.49 billion in Q3 FY16, thereby reporting a 14.03% increase. The reason for the considerable hike in revenue was attributed to the $7.2 billion acquisition of Patheon, favorable foreign exchange conditions, and good operational results of the Company. The reported quarter revenues beat analysts' estimates of $5.03 billion, by $90 million.

The Company's product revenues amounted to $4.23 billion for the reported quarter, up 9.30% on a y-o-y basis. The service revenues, on the other hand, amounted to $884.2 million in Q3 FY17 compared to $624.4 million on a y-o-y basis in Q3 FY16, resulting in a 41.61% increase.

Thermo Fisher reported an increase of 13.41% in total costs and operating expenses amounting to $4.48 billion for Q3 FY17 compared to $3.95 billion in the year ago same period. The Company achieved a gross profit margin of 47.5% and an adjusted operating margin of 21.3% in Q3 FY17.

Thermo Fisher's net income increased 12.77% to $533.9 million in Q3 FY17 compared to $473.5 million on a y-o-y basis in Q3 FY16. The Company posted EPS of $1.35 in the reported quarter compared to $1.20 in Q3 FY16, thereby resulting in a 12.5% increase on a y-o-y basis. The non-GAAP EPS stood at $2.31 in Q3 FY17, which beat analysts' estimates by $0.06.

Segment Details

Thermo Fisher operates under four business segments, namely: (i) Life Sciences Solutions, (ii) Analytical Instruments, (iii) Specialty Diagnostics, and (iv) Laboratory Products and Services.

The revenues for the Life Sciences Solutions segment were $1.38 billion in Q3 FY17 compared to $1.31 billion on a y-o-y basis, resulting in a 5.34% increase. The segment's operating income amounted to $453.0 million for the reported quarter, while its adjusted operating margin increased to 32.8%.

The Analytical Instruments segment saw a rise in revenue of 32.22% to $1.19 billion on a y-o-y basis in Q3 FY17 from $0.90 billion in Q3 FY16. The segment's operating income amounted to $256.6 million for the reported quarter, while its adjusted operating margin increased to 21.60%.

The Specialty Diagnostics segment's revenues also rose to $0.84 billion in the reported quarter from $0.79 billion, resulting in a 6.33% increase on a y-o-y basis. The segment's operating income amounted to $218.8 million for the reported quarter, while its adjusted operating margin declined to 25.9%.

The revenues of the Laboratory Products and Services segment increased 15.57% to $1.93 billion in the reported quarter from $1.67 billion. The segment's operating income amounted to $243.4 million for the reported quarter, while its adjusted operating margin declined to 12.6%.

Balance Sheet

Thermo Fisher's current assets were $8.85 billion for Q3 FY17, a 26.06% rise from the $7.02 billion reported in Q4 FY16. The total assets amounted to approximately $56 billion in Q3 FY17 compared to $45.91 billion in Q4 FY16, an increase of 21.98%. Higher property, plant, and equipment, and acquisition-related intangibles, and goodwill resulted in a better total assets figure for the reported quarter.

The Company's total current liabilities rose 44.35% to $7.03 billion in the reported quarter from $4.87 billion in Q4 FY16. The short-term obligations doubled in Q3 FY17 compared to Q4 FY16, resulting in a 44.35% rise in the total current liabilities figures.

The third major component of the balance sheet, which is shareholder's equity, amounted to $24.70 billion compared to $21.54 billion in Q4 FY16, resulting in a 14.67% rise.

Cash Matters

Thermo Fisher reported net cash inflow from operating activities to the tune of $2.14 billion in Q3 FY17 compared to $2.05 billion on a y-o-y basis. The 4.39% increase in cash inflow was due to higher net income generated in the reported quarter.

The net cash outflow from investing activities rose 37.20% to $7.45 billion in the reported quarter from $5.43 billion in Q3 FY16. The increase in cash outflow was due to higher acquisition costs borne by the Company in the reported quarter.

The Company reported net cash inflow from financing activities of $5.00 billion in Q3 FY17 compared to $4.95 billion on a y-o-y basis, rising by a minimal 1.01%.

Outlook

Thermo Fisher posted positive earnings for the reported quarter, beating analysts' estimates for revenue and EPS. The analysts have estimated an EPS of $2.6 for Q3 FY18, and 2.67 for Q4 FY17. The EPS is estimated at $9.36 for the fiscal year 2017, and $10.55 for the fiscal year 2018.

Stock Performance

Thermo Fisher Scientific's share price finished yesterday's trading session at $191.89, sliding 1.02%. A total volume of 1.01 million shares have exchanged hands. The Company's stock price surged 10.77% in the last three months, 11.88% in the past six months, and 26.20% in the previous twelve months. Additionally, the stock soared 36.00% since the start of the year. Shares of the Company have a PE ratio of 32.60 and have a dividend yield of 0.31%. The stock currently has a market cap of $75.58 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.